Related Experiment Videos

Clinical pharmacology of cefotaxime in pediatric patients

Insights

Cefotaxime effectively treated infections in 97% of pediatric patients with minimal toxicity. This cephalosporin demonstrated favorable pharmacokinetics in infants and children, similar to adults, supporting its use in pediatric infectious diseases.

Area of Science:

  • Pharmacology
  • Pediatric Infectious Diseases
  • Antimicrobial Therapy

Background:

  • Cefotaxime is a third-generation cephalosporin antibiotic.
  • Its broad spectrum of activity suggests potential utility in pediatric populations.

Purpose of the Study:

  • To evaluate the efficacy and safety of cefotaxime in infants and children.
  • To characterize the pharmacokinetic profile of cefotaxime in this age group.

Main Methods:

  • Cefotaxime was administered to 33 pediatric patients.
  • Clinical outcomes, pathogen eradication, and adverse events were monitored.
  • Pharmacokinetic parameters including elimination half-life, volume of distribution, and clearance were determined.

Main Results:

  • 97% of patients experienced clinical cure or improvement.
  • 94% of isolated pathogens were eradicated.
  • Toxicity was minimal.
  • Pharmacokinetic parameters in pediatric patients were comparable to adult data (elimination half-life ~1.5 h, Vd 1 L/kg, CL 10 mL/min/kg).

Conclusions:

  • Cefotaxime is an effective and well-tolerated antibiotic for treating infections in pediatric patients.
  • The pharmacokinetic disposition of cefotaxime in infants and children is similar to adults, supporting its therapeutic use.

Related Concept Videos